RxDoctor Payments Data

Rachel Bryan, APRN

Family · Trumbull, CTNPI 1316322696

Payments from drug & device makers

$1,151in general payments, 2019–2025

Across 51 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$259
  • Travere Therapeutics, Inc.$256
  • Ardelyx, Inc.$244
  • Akebia Therapeutics Inc$175
  • Otsuka America Pharmaceutical, Inc.$85
  • Fresenius USA Marketing, Inc.$37
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$1,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,151 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,833
Medicare patients
55
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl67$203,225
FarxigaDapagliflozin Propanediol59$40,313
AuryxiaFerric Citrate16$34,005
Sevelamer Carbonate159$28,173
LokelmaSodium Zirconium Cyclosilicate24$15,471
Calcium Acetate81$6,628
ClinolipidFat Emulsion/Olive/Soy/Phospho19$4,243
ProsolParenteral Amino Acid 20% No.129$3,461
Midodrine Hcl51$1,599
Calcitriol136$1,447
Torsemide15$638
Hydralazine Hcl56$635
Losartan Potassium36$396
Amlodipine Besylate75$387
Allopurinol22$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$259$55,78483 claims
Akebia Therapeutics IncAuryxia$175$34,00516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →